Sophia Abene

Eloise Williams, MBBS, BMedSci, MPHTM, FRACP, FRCPA, details how an 8-criterion genomics-plus-clinical framework narrowed 5,881 isolates to 5 strains while prioritizing safety and contemporary relevance.

TNX-4800 targets OspA to block Borrelia transmission; positive phase 1 data reported and an adaptive phase 2/3 study is planned.

Vincent Lo Re, MD, MSCE, FISPE, reviews HR-pQCT findings, IL-18 and TNF-α declines, and guidance for clinicians.

Catherine M. Stein, Evelyn Griffin, Hilary Blackburn, Kirk Milhoan, and Raymond Pollak join ACIP as the panel prepares to vote on MMRV, hepatitis B, and COVID-19 recommendations following the June reconstitution.

Shin Hye Yoo, MD, PhD, on a nationwide cohort showing end-of-life antibiotic use clusters in the final months, is higher in hematologic cancers, and offers a window for stewardship and goal-concordant care.

Sean Tucker, PhD, discusses the immunogenicity readouts, why mucosal markers matter, and what’s next as the program moves toward phase 2b.

At the ICE-HBV Cure Symposium, EBT-107 showed reduced intrahepatic HBV DNA and no increase in chromosomal translocations, supporting a path toward first-in-human testing.

Democratic Republic of the Congo reports 28 suspected cases and 15 deaths, as Africa CDC and WHO mobilize vaccines, surveillance, and rapid response teams to contain the 16th Ebola outbreak since 1976.

This week, US measles totals reached 1,454, a 750-plus-day SARS-CoV-2 infection in a person with HIV informed care, implementation science efforts advanced access, and a universal flu adjuvant showed promise.

CDC’s recent ArboNET snapshot shows widespread human and non-human activity, preliminary totals subject to change, and no lineage reporting on the dashboard.

Record-high 127.1/100,000 hospitalizations with co-circulating influenza A strains and similar in-hospital severity to prior years.

Head-to-head phase 1 data indicate larger fecal IgA responses after a single tablet vs first-generation constructs, with plans to advance to mid-stage testing.

Oxford’s Prof Katrina Lythgoe and Mahan Ghafari, DPhil, report ONS-CIS data on 576 persistent UK infections with rapid within-host evolution and rare transmission after one month.

CDC reports 3 new cases this past week, bringing the 2025 total to 1,454 confirmed cases across 42 jurisdictions, with 37 outbreaks.

William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.

16 cases of Salmonella Enteritidis across 10 states, including seven hospitalizations, are under investigation; antimicrobial resistance may complicate treatment.

Cocrystal Pharma to launch phase 1b study by year-end 2025, targeting prevention and treatment of viral gastroenteritis caused by norovirus.

41 cases of nongroupable N meningitidis conjunctivitis were identified at Joint Base San Antonio-Lackland, highlighting diagnostic, treatment, and surveillance implications for congregate living settings.

From COVID-19 antivirals to RSV, influenza, malaria, and gram-negative infections, new research highlights both advances and ongoing challenges in infectious disease prevention and treatment.

Up to 2 million people in low- and lower-middle-income countries may gain access to the long-acting PrEP option under a three-year, no-profit agreement.

The financing supports phase 3 evaluation of Sidiprev, a first-in-class, nonantibiotic therapy designed to prevent C difficile infections, a leading US health care–associated threat.

WHO and HRP highlight new research on HIV communication, STI priorities, and inclusive strategies to strengthen sexual health worldwide.

Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.

Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.

In the DAN-RSV trial of 131,000 participants, RSVpreF lowered overall cardiorespiratory hospitalizations but showed no significant reduction in cardiovascular events.

Results from a Danish trial of more than 330,000 adults 65 years or older found high- and standard-dose influenza vaccines had similar effectiveness against influenza or pneumonia-related hospitalizations.

This week, expert insights highlighted progress in reducing C difficile with electronic hand hygiene monitoring, advancing HIV prevention with lenacapavir, updating COVID-19 vaccines for high-risk groups, and more.

Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.

CDC encourages travelers to take enhanced precautions, get vaccinated, and prevent mosquito bites in affected areas, with special warnings for pregnant individuals.

NYC officials confirm 113 cases and six deaths in Central Harlem cooling tower–linked outbreak; separate Bronx investigation underway after cases tied to hot water system.